DE60144291D1 - Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen - Google Patents

Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen

Info

Publication number
DE60144291D1
DE60144291D1 DE60144291T DE60144291T DE60144291D1 DE 60144291 D1 DE60144291 D1 DE 60144291D1 DE 60144291 T DE60144291 T DE 60144291T DE 60144291 T DE60144291 T DE 60144291T DE 60144291 D1 DE60144291 D1 DE 60144291D1
Authority
DE
Germany
Prior art keywords
aztreonam
treatment
formulation
inhibitable
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60144291T
Other languages
English (en)
Inventor
Alan Bruce Montgomery
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22980480&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60144291(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DE60144291D1 publication Critical patent/DE60144291D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE60144291T 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen Expired - Lifetime DE60144291D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25842300P 2000-12-27 2000-12-27
PCT/US2001/050062 WO2002051356A2 (en) 2000-12-27 2001-12-20 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections

Publications (1)

Publication Number Publication Date
DE60144291D1 true DE60144291D1 (de) 2011-05-05

Family

ID=22980480

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60144291T Expired - Lifetime DE60144291D1 (de) 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen
DE201112100043 Pending DE122011100043I1 (de) 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE201112100043 Pending DE122011100043I1 (de) 2000-12-27 2001-12-20 Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen.

Country Status (19)

Country Link
US (6) US6660249B2 (de)
EP (2) EP1353647B1 (de)
JP (1) JP4646489B2 (de)
AT (1) ATE502623T1 (de)
AU (1) AU2002231244B2 (de)
BE (1) BE2011C029I2 (de)
BR (1) BRPI0116757B8 (de)
CA (2) CA2708703C (de)
CY (2) CY1111571T1 (de)
DE (2) DE60144291D1 (de)
DK (2) DK2301524T3 (de)
ES (2) ES2406405T3 (de)
FR (1) FR11C0030I2 (de)
IL (3) IL156596A0 (de)
LU (1) LU91851I2 (de)
NL (1) NL300492I2 (de)
NO (3) NO329643B1 (de)
PT (2) PT1353647E (de)
WO (1) WO2002051356A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
ES2406405T3 (es) * 2000-12-27 2013-06-06 Gilead Sciences, Inc. Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares
US20030133925A1 (en) * 2001-09-28 2003-07-17 Shawar Ribhi M. Monobactam compositions and methods of use thereof
US20030224039A1 (en) * 2002-03-05 2003-12-04 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7145017B2 (en) 2002-08-05 2006-12-05 TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság Preparation of Aztreonam
WO2004052333A1 (en) * 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1617820B1 (de) 2003-04-14 2018-03-21 Vectura Limited Trockenpulverinhalatoren und trockenpulverformulierungen zum erhöhen der dosierleistung
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
CA2526362C (en) * 2003-05-20 2012-10-09 James F. Collins Ophthalmic drug delivery system
CA2733145C (en) * 2003-07-02 2012-06-19 Corus Pharma, Inc. Aztreonam l-lysine and method of determining impurities therein
AU2014271333B2 (en) * 2003-07-03 2016-10-27 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
AU2004257632C1 (en) * 2003-07-03 2010-04-15 Gilead Sciences, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
US7452523B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
DE602006005240D1 (de) 2005-05-09 2009-04-02 Sicor Inc Herstellungsverfahren für aztreonam
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
HUP0700007A2 (en) * 2007-01-08 2008-10-28 Asthma Rehabilitacios Ct Kft Device and process for producing of natrium chloride aerosol for the disorders of the respiratory system
EP2155251B1 (de) * 2007-05-08 2013-09-25 Rq Bioscience, Inc. Therapeutische zusammensetzungen und verfahren zur behandlung gram-negativer bakterieller infektionen
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
EA201070336A1 (ru) * 2007-10-01 2011-06-30 Джилид Сайэнс, Инк. Ингаляционный азтреонам лизин для лечения нарушений, снижающих качество жизни, обусловленное состоянием здоровья при заболеваниях легких
JP5639475B2 (ja) * 2007-11-27 2014-12-10 アルギファルマ アイピーアール エーエス バイオフィルムと闘う際のアルギネートオリゴマーの使用
EP2098219A1 (de) 2008-03-05 2009-09-09 PARI Pharma GmbH Makrolidzusammensetzungen mit verbessertem Geschmack und verbesserter Stabilität
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
BRPI1011721B1 (pt) 2009-03-26 2021-11-16 Pulmatrix, Inc Formulações em pó seco inaláveis compreendendo sal de cátion de metal divalente e métodos para tratar doenças pulmonares
DK2437784T3 (da) 2009-06-03 2014-01-27 Algipharma As Alginatoligomerer til anvendelse i overvindelse af multidrug resistens i bakterier
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
US20120076859A1 (en) * 2010-09-23 2012-03-29 Activaero Gmbh Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases
KR20180122475A (ko) 2010-09-29 2018-11-12 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
ES2899621T3 (es) 2010-09-29 2022-03-14 Pulmatrix Operating Co Inc Polvos secos catiónicos que comprenden sal de magnesio
WO2013109217A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Pharmaceutical formulations comprising aztreonam
NZ629722A (en) 2012-02-29 2017-03-31 Pulmatrix Operating Co Inc Inhalable dry powders
EP2978434A4 (de) * 2013-03-28 2016-08-17 Pharmacaribe Llc Zusammensetzungen, formulierungen und verfahren zum bioausgleich des ph-werts einer sterilen isotonischen salzlösung und von hypertonischen salzlösungen
RU2015146871A (ru) 2013-04-01 2017-05-10 Пулматрикс, Инк. Сухие порошки с тиотропием
CN104784159A (zh) * 2015-04-15 2015-07-22 苏州惠仁生物科技有限公司 氨曲南粉雾剂的制备方法
WO2017192778A1 (en) 2016-05-03 2017-11-09 Pneuma Respiratory, Inc. Systems and methods for pulmonary health management
WO2018213834A1 (en) 2017-05-19 2018-11-22 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
CN115300226A (zh) 2017-06-10 2022-11-08 艾诺维亚股份有限公司 用于将一体积的流体输送到眼睛的设备
US11738158B2 (en) 2017-10-04 2023-08-29 Pneuma Respiratory, Inc. Electronic breath actuated in-line droplet delivery device and methods of use
CA3079189A1 (en) 2017-10-17 2019-04-25 Pneuma Respiratory, Inc. Nasal drug delivery apparatus and methods of use
JP2021502178A (ja) 2017-11-08 2021-01-28 ニューマ・リスパイラトリー・インコーポレイテッド 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法
CN110898040B (zh) * 2018-09-18 2022-05-17 北京盈科瑞创新药物研究有限公司 一种吸入用氨曲南溶液用冻干粉及其制备方法
CN111647537B (zh) * 2020-06-18 2022-04-26 浙江工业大学 一种耐盐辣椒素降解菌、应用及餐厨垃圾处理方法
KR20240037245A (ko) 2021-06-22 2024-03-21 뉴마 레스퍼러토리 인코포레이티드 푸시 이젝션에 의한 액적 전달 장치

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9126A (en) * 1852-07-13 Marcus r
US572801A (en) * 1896-12-08 Telephone-exchange
US610824A (en) * 1898-09-13 Sleigh attachment for vehicles
US673739A (en) * 1900-09-19 1901-05-07 Frank B Stearns Driving mechanism for vehicles.
US775670A (en) * 1904-08-17 1904-11-22 Thomas F Whittelsey Air-brake safety device.
US946838A (en) * 1909-08-17 1910-01-18 George Dawson Tempering compound.
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4673739A (en) 1980-12-05 1987-06-16 Takeda Chemical Industries, Ltd. 4-carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
US4529698A (en) * 1981-01-19 1985-07-16 E. R. Squibb & Sons, Inc. Process for preparing a 2-oxo-1-azetidinesulfonic acid salt
US4625022A (en) * 1981-02-02 1986-11-25 E. R. Squibb & Sons, Inc. Process for preparing (s)-3-amino-2-oxo-1-azetidinesulfonic acid salts
US4386034A (en) * 1981-02-02 1983-05-31 E. R. Squibb & Sons, Inc. Sulfamated amino acid amides
US4572801A (en) 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
CA1181075A (en) 1981-07-13 1985-01-15 David M. Floyd CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID
US4946838A (en) 1981-07-13 1990-08-07 E. R. Squibb & Sons, Inc. Crystalline anhydrous aztreonam
US4752469A (en) * 1984-01-09 1988-06-21 E. R. Squibb & Sons, Inc. Potentiators of beta-lactam antibiotics
US4826973A (en) * 1984-07-20 1989-05-02 E. R. Squibb & Sons, Inc. Delta form of aztreonam and preparation thereof
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US4888998A (en) * 1986-07-11 1989-12-26 Beckman Instruments, Inc. Sample handling system
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5194604A (en) * 1990-06-29 1993-03-16 E. R. Squibb & Sons, Inc. Process and intermediates for beta-lactams having aminothiazole(iminooxyacetic acid)acetic acid sidechains
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2105629A1 (en) * 1992-09-14 1994-03-15 Robert S. Becker Potentiation of immunogenic response
PT754050E (pt) * 1994-01-14 2002-11-29 Xoma Technology Ltd Metodos e materiais contra bacterias gram-positivas
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5662929A (en) * 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
WO1998009990A1 (fr) 1996-09-04 1998-03-12 Takara Shuzo Co., Ltd. Antigenes fongiques et processus de fabrication
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2410694A1 (en) 1998-06-16 1999-12-16 Serge Dea Porcine reproductive and respiratory syndrome virus (prrsv) dna vaccines
CA2514899A1 (en) 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells and compositions
HUP0105226A3 (en) * 1998-12-17 2003-03-28 Pathogenesis Corp Seattle Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
JP2003502292A (ja) 1999-06-01 2003-01-21 バイオジェン インコーポレイテッド ヘッジホッグタンパク質のポリマー結合体及び利用
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
IL149085A0 (en) * 1999-10-29 2002-11-10 Inhale Therapeutic Syst A dry powder composition containing a di or tripeptide
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
ES2406405T3 (es) * 2000-12-27 2013-06-06 Gilead Sciences, Inc. Aztreonam inhalable sin arginina para tratamiento y prevención de infecciones bacterianas pulmonares
US7138419B2 (en) * 2000-12-27 2006-11-21 Corus Pharma, Inc. Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate
US7214364B2 (en) * 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
JP2005505441A (ja) * 2001-10-08 2005-02-24 カリフォルニア インスティテュート オブ テクノロジー 微小加工レンズ、その製造の方法および応用
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
US20030224039A1 (en) 2002-03-05 2003-12-04 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
EP1417958A1 (de) 2002-11-08 2004-05-12 Pari GmbH Feuchtgranulierungsverfahren
WO2004052333A1 (en) 2002-12-11 2004-06-24 Pari Gmbh Pharmaceutical compositions for the pulmonary delivery of aztreonam
CA2733145C (en) 2003-07-02 2012-06-19 Corus Pharma, Inc. Aztreonam l-lysine and method of determining impurities therein
EA201070336A1 (ru) 2007-10-01 2011-06-30 Джилид Сайэнс, Инк. Ингаляционный азтреонам лизин для лечения нарушений, снижающих качество жизни, обусловленное состоянием здоровья при заболеваниях легких

Also Published As

Publication number Publication date
PT1353647E (pt) 2011-05-24
US7208141B2 (en) 2007-04-24
EP1353647A2 (de) 2003-10-22
CA2708703C (en) 2012-12-04
LU91851I2 (fr) 2011-10-03
NO329643B1 (no) 2010-11-22
US20030055034A1 (en) 2003-03-20
US20140037735A1 (en) 2014-02-06
IL156596A0 (en) 2004-01-04
US20080050439A1 (en) 2008-02-28
BRPI0116757B8 (pt) 2021-05-25
BR0116757B1 (pt) 2014-02-04
ES2406405T3 (es) 2013-06-06
BR0116757A (pt) 2003-11-04
EP2301524B1 (de) 2013-04-24
CY2011012I1 (el) 2014-04-09
NL300492I2 (nl) 2017-11-02
LU91851I9 (de) 2019-01-03
IL221036A0 (en) 2012-08-30
DE122011100043I1 (de) 2011-12-15
WO2002051356A3 (en) 2002-10-31
US9533000B2 (en) 2017-01-03
EP1353647B1 (de) 2011-03-23
DK1353647T3 (da) 2011-06-14
AU2002231244B2 (en) 2006-06-29
PT2301524E (pt) 2013-07-10
US20120093890A1 (en) 2012-04-19
ATE502623T1 (de) 2011-04-15
NO2011001I2 (no) 2013-05-27
CA2433280A1 (en) 2002-07-04
EP1353647A4 (de) 2007-05-09
FR11C0030I2 (fr) 2012-03-16
IL156596A (en) 2012-07-31
NO20101377L (no) 2003-08-26
US20050129623A1 (en) 2005-06-16
NO20032946D0 (no) 2003-06-26
US20170296517A1 (en) 2017-10-19
NO20032946L (no) 2003-08-26
DK2301524T3 (da) 2013-07-15
CA2433280C (en) 2010-09-21
JP2004516302A (ja) 2004-06-03
CA2708703A1 (en) 2002-07-04
NO2011001I1 (no) 2011-02-07
FR11C0030I1 (de) 2011-09-23
BE2011C029I2 (de) 2021-07-26
WO2002051356A2 (en) 2002-07-04
EP2301524A1 (de) 2011-03-30
ES2360692T3 (es) 2011-06-08
CY1111571T1 (el) 2014-04-09
US6660249B2 (en) 2003-12-09
CY2011012I2 (el) 2014-04-09
JP4646489B2 (ja) 2011-03-09

Similar Documents

Publication Publication Date Title
DE60144291D1 (de) Inhalierbares aztreonam zur behandlung und vorbeugung von bakteriellen lungeninfektionen
CY1114621T1 (el) Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων
WO2011005354A3 (en) Gallium formulation for the treatment and prevention of infectious diseases
NZ631469A (en) Aerosol fluoroquinolone formulations for improved pharmacokinetics
WO2003097575A3 (en) Amino-functional chalcones
EP1057828A3 (de) Trovafloxacin enhaltende Suspensionen zur oralen Anwendung
EP1435357A3 (de) Neues Verfahren zur Herstellung von Vinyl-Pyrrolidin Cephalosporin Derivaten
WO2001097791A3 (fr) Utilisation d'acides en c4-c10 pour la prévention des infections a bactéries a gram négatif
CY1114144T1 (el) Εισπνευσιμη αζτρεοναμη για τη θεραπεια και την προληψη πνευμονικων βακτηριακων λοιμωξεων
AR040420A1 (es) Aztreonam inhalable para el tratamiento y la prevencion de infecciones bacterianas pulmonares
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
BR0317425A (pt) Sal de rabeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
BR0307468A (pt) Derivados tiadiazinona antimicrobianos úteis no tratamento de infecções bacterianas
CA2468033A1 (en) A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales
GR1003520B (el) Μεθοδος χρησης ενωσεων φλουοροκινολονης εναντια σε νοσοκομειακα αρνητικα κατα gramμ παθογενων βακτηριδιων
IL172768A0 (en) Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Legal Events

Date Code Title Description
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: ZUSAMMENSETZUNG ENTHALTEND AZTREONAM, NICHT IN EINER ZUSAMMENSETZUNG MIT ARGININ, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ VON AZTREONAM, DAS KEIN ARGININSALZ IST; REGISTRATION NO/DATE: EU/1/09/543/001 20090921

Spc suppl protection certif: 122011100043

Filing date: 20110822

Free format text: PRODUCT NAME: ZUSAMMENSETZUNG ENTHALTEND AZTREONAM, NICHT IN EINER ZUSAMMENSETZUNG MIT ARGININ, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ VON AZTREONAM, DAS KEIN ARGININSALZ IST; REGISTRATION NO/DATE: EU/1/09/543/001 20090921

Spc suppl protection certif: 122011100043

Filing date: 20110822

Expiry date: 20211221

Effective date: 20111025

Free format text: PRODUCT NAME: AZTREONAMLYSIN; REGISTRATION NO/DATE: EU/1/09/543/001 20090921

Spc suppl protection certif: 122011100043

Filing date: 20110822

Expiry date: 20211221

Effective date: 20111025